Last reviewed · How we verify

NCT06088927: STIMU'HIS

Long-term Outcomes of Conduction System Pacing: a National Multicenter Observational Study - NORMAND'HIS / STIMU'HIS

Recruiting now Last updated 18 October 2023
What this trial tests

trial testing Conduction system pacing in Conduction System Pacing in 2,500 participants. Currently enrolling.

Timeline
1 March 2023
Primary endpoint
31 March 2028
31 March 2028

Quick facts

Lead sponsorUniversity Hospital, Rouen
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment2,500
Start date1 March 2023
Primary completion31 March 2028
Estimated completion31 March 2028
Sites10 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Rouen

Who can join

18 and older, any sex, with Conduction System Pacing. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective multicenter registry will evaluate the long-term electrical, echocardiographic, and clinical outcomes of conduction system pacing (CSP). There is currently limited data in the literature regarding the long-term results and benefits of CSP. The long-term maintenance of conduction system (His bundle or Left Bundle Branch) capture and physiological ventricular activation is an essential prerequisite for the expected benefits of this technique. There is currently no prospective study evaluating the preservation of CSP during long-term follow-up. The design of the present study will allow reliable evaluation of CSP maintenance at 2 years follow-up. The prospective collection of electrical data (pacing thresholds, impedance, R wave sensing) during pacemaker follow-up visits will confirm thresholds stability over the long term. The incidence of atrial fibrillation episodes will also be precisely evaluated and will provide new information. Although pathophysiological studies have demonstrated less impairment of left atrial function with conduction system pacing, there is currently no data on the incidence of atrial fibrillation in patients implanted with a CSP pacemaker. Echocardiographic data will be prospectively collected in order to analyse the evolution of left ventricular ejection fraction (LVEF) after CSP. This systematic follow-up is rarely found in CSP studies, often retrospective, with significant missing echocardiographic data. The hypothesis is that patients benefiting from CSP will not develop the deleterious effects demonstrated with conventional right ventricular pacing, such as left ventricular dilation and LVEF impairment. Inter- and intraventricular asynchrony criteria will also be systematically evaluated during follow-up echocardiography.Finally, this prospective cohort will also systematically collect clinical follow-up data (hospitalizations for heart failure and NYHA stage).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Conduction system pacing

Trials testing the same drug.

Other recruiting trials for Conduction System Pacing

Currently open trials in the same condition.

Other University Hospital, Rouen trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06088927.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing